Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 13Lymphoid 13Gastrointestinal 12Breast 11Other solid neoplasm 7Dermatologic 7Sarcoma 6Thoracic 5Head & Neck 4CNS 4Plasma cell 3Myeloid 3Gynecologic 3Tumor-Agnostic 1Genitourinary 1Endocrine 1Classical hematology 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pharmacogenomic Testing × Endocrine × Clear all
NCT00381641 2025-03-28

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
63 enrolled 12 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡